# Meningococcal Vaccines—High-risk Populations

Different vaccines protect against different serogroups.

## Risk groups:
- **Exp. Increased Exposure to meningococcal serogroups covered by vaccines** (due to outbreaks, travel to affected areas [e.g. the Hajj], lab exposure)
- **CD. Persistent Complement component Deficiencies** (including persons taking eculizumab [Soliris®])
- **Asp. Functional or Anatomic Asplenia** (including sickle cell disease)
- **HIV. HIV Infection**

## Age at first dose | Exp | CD | Asp | HIV | 1) MenACWY vaccines* | Boosters for those who remain at increased risk
--- | --- | --- | --- | --- | --- | ---

### 2–6 months
- 2 months
- 4 months
- 6 months
- 12–15 months

- **ACWY-CRM Menveo®**
- **ACWY-CRM Menveo®**
- **ACWY-CRM Menveo®**
- **ACWY-CRM Menveo®**

If primary dose(s) given when younger than 7 years:
- **ACWY-CRM or -D Menveo®**
- **ACWY-CRM or -D Menactra®**
- **Every 5 years**

If primary dose(s) given at age 7 years or older:
- **ACWY-CRM or -D Menveo®**
- **ACWY-CRM or -D Menactra®**

### 7–23 months
- 3 months

- **ACWY-CRM Menveo®**
- **ACWY-CRM Menveo®**

### 9–23 months
- 3 months

- **ACWY-D Menactra®**
- **ACWY-D Menactra®**

### 2 years and older
- 2 months

- **ACWY-CRM or -D Menveo®**
- **ACWY-CRM or -D Menactra®**

### 2) Also give MenB vaccine—may be given at same time as MenACWY vaccine. Use the same brand for each dose in the series.

### 10 years and older
- 1 month

- **MenB-4C Bexsero®**
- **MenB-4C Bexsero®**
- **MenB-FHbp Trumenba®**
- **MenB-FHbp Trumenba®**
- **MenB-FHbp Trumenba®**
- **6 months between 1st and 3rd dose**

* For further details, see [www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html](http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html). For routine use, see recommendations at EZIZ.org/assets/docs/IMM-1217.pdf.

1. For information on current meningococcal outbreaks, see [www.cdph.ca.gov/HealthInfo/discond/Pages/MeningococcalDisease.aspx](http://www.cdph.ca.gov/HealthInfo/discond/Pages/MeningococcalDisease.aspx)
2. Abbreviations: ACWY/ACWY-CRM/ACWY-D = MenACWY = MCV4
3. Minimum age 12 months.
4. MenACWY-D (Menactra®) is licensed starting at 9 months.
5. If MenACWY-D (Menactra®) is used for persons with asplenia or HIV infection, defer until age 2 years and at least 4 weeks after completion of PCV13 series.
6. It is recommended that MenACWY-D be given either before, or concomitantly with, the next recommended dose of DTaP vaccine.